Welcome to our dedicated page for Kraig Biocraft Laboratories news (Ticker: $KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kraig Biocraft Laboratories's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kraig Biocraft Laboratories's position in the market.
Kraig Biocraft Laboratories (OTCQB: KBLB) announces the production of its BAM-1 recombinant spider silk hybrids, ahead of schedule due to successful production trials. This marks the company’s first true production-scale launch of these hybrids, representing over a 10x increase in production compared to spring trials. The BAM-1 hybrids, created by integrating Dragon Silk™ with robust silkworm strains, have shown excellent hatching yields, strong growth, and no signs of disease. This cycle aims to reach a production milestone of a metric ton of spider silk, with further updates promised in the coming weeks.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced significant advancements in the commercialization of its BAM-1 recombinant spider silk production hybrids, first introduced in February 2024. The BAM-1 platform has proven to be the most resilient and efficient system for large-scale spider silk production. This technology has successfully integrated the desirable properties of spider silk into production-ready silkworm strains, resulting in the advanced Dragon SilkTM. CEO Kim Thompson emphasized the scalability and reliability of the BAM-1 hybrids in accelerating the market transition of spider silk technologies. Following successful spring production trials, the company is ahead of its 2024 production schedule and plans to expand production further in the coming weeks.
Kraig Biocraft Laboratories (OTCQB: KBLB) has completed its spring spider silk production trials and is set to expand production in 2024. The company identified five key input parameters—nutrition, climate, genetic, staffing, and rearing conditions—that improved silkworm genetics and production processes, resulting in the largest and strongest silkworms and cocoons to date. Under the guidance of Dr. Nirmal Kumar, the team achieved significant advancements and is now accelerating the launch of larger-scale operations, starting nearly a month ahead of schedule with the next generation of BAM-1 spider silk hybrids.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced significant milestones, particularly the success of its spring production trials for spider silk. The company has heightened its investor communications and reviewed its investor relations (IR) program at the request of OTC Markets Group, ensuring all publications are compliant and factual. A recent editorial by 24/7 Market News highlighted advancements in spider silk, which the company verified as truthful. Kraig Labs has directed Hansel Capital and Karolus Maximus Kapital to provide shareholder updates, emphasizing a commitment to compliance and transparency. The company reported no insider trading or issuance of common stock in the past 90 days, except for the CEO acquiring one restricted share. Kraig Biocraft is focused on scaling production and maintaining high reporting standards.
Kraig Biocraft Laboratories, Inc. announces plans to expand production base into Cambodia to support the growth of its recombinant spider silk production. The Company's successful spring production trials have paved the way for rapid expansion and diversification of operations. With a target of one metric ton production before year's end, the Company aims to capitalize on its recent successes and continue scaling up its operations.
Kraig Biocraft Laboratories (KBLB) has successfully completed its Spring spider silk trials, exceeding expectations and paving the way for commercial scale production of genetically bioengineered spider silk. The trials showcased the strength and resilience of the BAM-1 recombinant spider silk hybrids, with no instances of disease or infection throughout the entire production cycle. Dr. Nirmal Kumar, an expert consultant, oversaw the selective breeding process, optimizing the parental strains for larger cocoons and improved reeling characteristics. The results have positioned Kraig Labs to scale production to metric ton levels.
Kraig Biocraft Laboratories, Inc. (KBLB) announces successful spring production trials of its BAM-1 hybrid parental strains, exceeding expectations for scale, performance, and robustness. The trials demonstrated the readiness for rapid production expansion, marking the most successful cycle in the company's history. The parent strains showed strength and resilience, with no instances of disease. The company is now moving towards scaling production to metric ton levels.
Kraig Biocraft Laboratories, Inc. announces successful spring production trials for their BAM-1 hybrid parental strains, exceeding all expectations for scale, performance, and robustness. The trials demonstrated that the Company's BAM-1 recombinant spider silk hybrids are ready for rapid production expansion. Renowned expert Dr. Nirmal Kumar oversaw the production, resulting in the strongest and most resilient silkworm lines developed by Kraig Labs. The Company is now prepared to scale production to metric ton levels, targeting multiple production locations in multiple countries.
Kraig Biocraft Laboratories, Inc. reports signing landmark agreements with the Lam Dong Agro-Forestry Research Experiment Center in Vietnam for rearing and breeding specialized silkworms. The agreements outline a collaborative effort to integrate the Company's silk technologies, with the LAREC providing insights and assistance in selective breeding of the BAM-1 parental strains for local conditions. This strengthens the collaboration between Kraig Labs and governmental agencies in South East Asia, expanding the Company's operations.